Skip to main content
. 2008 Nov-Dec;2(6):287–294.

Figure 1.

Figure 1.

Comparison of overall survival of (A) patients with complete chemotherapy for 3 months48 and (B) patients with metabolic response-based neoadjuvant treatment.55 The median survival was 26 months in metabolic nonresponding patients with immediate resection after 2 weeks and 18 months in patients with complete chemotherapy in the historical control group. Stopping chemotherapy, thus, seems not to worsen prognosis of metabolic nonresponding patients.